Objectives To evaluate the clinical features of erythromelalgia in childhood associated with gain-of-function SCN9A mutations that increase activity of the Nav1.7 voltage-gated sodium channel, we conducted a systematic review of pediatric presentations of erythromelalgia related to SCN9A mutations, and compared pediatric clinical presentations of symptomatic erythromelalgia, with or without SCN9A mutations.
Results Twenty-eight publications described erythromelalgia associated with 15 different SCN9A gene variants in 25 children. Pain was severe and often refractory to multiple treatments, including nonspecific sodium channel blockers. Skin damage or other complications of cold immersion for symptomatic relief were common (60%). SCN9A mutations resulting in greater hyperpolarizing shifts in Nav1.7 sodium channels correlated with symptom onset at younger ages (P = .016). Variability in reporting, and potential publication bias toward severe cases, limit any estimations of overall prevalence. In our case series, symptoms were similar but comorbidities were more common in children with SCN9A mutations. Quantitative sensory testing revealed marked dynamic warm allodynia.
Conclusions Inherited erythromelalgia in children is associated with difficult-to-manage pain and significant morbidity. Standardized reporting of outcome and management in larger series will strengthen identification of genotype-phenotype relationships. More effective long-term therapies are a significant unmet clinical need. (J Pediatr 2019; 206:217-24) . E rythromelalgia is a rare but difficult-to-manage condition in children. 1 Bilateral episodic pain and redness occur in the feet, hands, and occasionally the ears. Symptoms may also progress proximally to include the legs and arms and rarely the face. 2 Pain is aggravated by heat and relieved by cooling or immersion in iced water. Diagnosis has been based on clinical features, 3, 4 with pathophysiology previously attributed to vascular, inflammatory, or neuropathic causes. However, since 2004, cases of inherited erythromelalgia have been linked to dominant gain-of-function mutations of the SCN9A gene and resultant alterations in function of a voltage-gated sodium channel Nav1.7. 5, 6 In addition, similar symptoms associated with autoimmune or myeloproliferative disorders 4, 7 have been reported in adults and termed "secondary erythromelalgia," but are extremely rare in children.
Voltage-gated sodium channels (Nav1.1 to Nav1.9) are encoded by a family of SCN genes and are differentially distributed throughout the nervous system, heart, and muscle. In children, sporadic or inherited mutations that affect different voltagegated sodium channels have been associated with epilepsy, cardiac conduction, and skeletal muscle abnormalities, 8 with treatment often reliant on nonspecific sodium channel blockers such as mexiletine. [9] [10] [11] Nav1.7 channels are expressed in peripheral nociceptive sensory neurons within dorsal root ganglia (DRG) and trigeminal ganglia, and in sympathetic ganglion neurons, and play a crucial role in pain sensitivity. 12, 13 Gain-of-function mutations with inherited erythromelalgia typically increase excitability of DRG neurons by hyperpolarizing the DRG Dorsal root ganglion GOSH Great Ormond Street Hospital NHS National Health Service PEPD Paroxysmal extreme pain disorder QST Quantitative sensory testing s-EM Symptomatic erythromelalgia
voltage-dependence of activation of Nav1.7 channels (making the channels easier to activate), slowing channel deactivation (channels remain open longer), and increasing the response to slow ramp-like stimuli (increasing the gain). 13, 14 Importantly, the site of mutation can influence both the abnormality of Nav1.7 channel function, and age of onset and severity of symptoms. 12, [15] [16] [17] Although reports in adults have evaluated phenotype-genotype relationships, 18 details of clinical evaluation during childhood and/or results of genetic testing have not been available in all pediatric case series. 1 We conducted a systematic review to identify cases of SCN9A-related inherited erythromelalgia reported during childhood. Data for genotype and clinical presentations, complications, and management were extracted. Our tertiary hospital chronic pain clinic experience managing children with erythromelalgia, in whom SCN9A mutations are present or absent, is summarized to suggest additional questions for future case series.
Methods
PRISMA guidelines were followed. 19 To identify reported symptoms, management, and complications of SCN9A-positive inherited erythromelalgia in children and young people, we searched PubMed (January 2004 to February 2017) using erythromelalgia (which also identified "erythermalgia") AND pediatric search terms (Figure 1 ; available at www.jpeds.com). Additional hand searches of reference lists and review articles, and a secondary search (erythromelalgia AND SCN9A) checked for further manuscripts including clinical details during childhood. Repeat searches in February 2018 identified recent publications fulfilling the inclusion criteria. No additional eligible publications were found from searching PsycINFO, EMBASE, or Cochrane databases. Authors reporting SCN9A-related inherited erythromelalgia pediatric cases in which the site of mutation was not reported were contacted for further details. Records were screened and restricted to those published in English since 2004, when erythromelalgia was first associated with mutations in SCN9A 6 and alterations in Nav1.7 channel gating and kinetics. 5 To specifically capture symptoms during childhood, included cases reported: clinical symptoms; age at time of reporting up to 18 years of age; SCN9A mutations and/or Nav1.7 substitutions; and individual data that could be extracted from group or family data. Cases in which an SCN9A mutation was reported without clinical details during childhood were excluded.
Citations deemed relevant by at least 1 reviewer underwent full-text screening. Two investigators independently reviewed selected articles. Available demographic data, clinical features, genetic testing results, complications and comorbidities, and management details were extracted, entered into a database, and cross-checked. Categories for which no details were available were labeled "not reported." Where earlier clinical descriptions were referenced, previous manuscripts including the same patient/family were grouped together.
Data were available as individual case series or case reports, which variably reported clinical details and may be biased to more severe presentations. Data related to symptoms, age at symptom onset, and time of report, management, and complications are summarized. Relative frequencies of complications are highlighted within the text. Values for the degree of hyperpolarizing shift in Nav1.7 activation were extracted for each reported mutation. Additional inherited erythromelalgia cases reported in adulthood but with documented onset during childhood are listed, and severe complications summarized. Children and young people with erythromelalgia aged 10-18 years were eligible for inclusion in a neuropathic pain cohort study (NHS Research Ethics Committee approval 17/WM/ 0306, 7-7-2017; Clinicaltrials.gov NCT03312881) that included quantitative sensory testing (QST). Following parental consent and child assent, we measured static thresholds for thermal (cool, warm, cold, heat) and mechanical (detection, pricking, pressure) stimuli, and dynamic allodynia for brush and thermal stimuli using a standardized QST protocol.
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increased sensitivity as positive values and decreased sensitivity as negative values. 25, 26 Results Descriptive Synthesis of Systematic Literature Review Twenty-eight manuscripts fulfilled the inclusion criteria (Figure 1 ) and reported 25 children and young people (<18 years of age at time of reporting) with clinical features of inherited erythromelalgia and confirmed SCN9A mutations producing 16 different substitutions of Nav1.7 channels. Six cases included clinical details and/or genetic analyses in sequential manuscripts, and 2 manuscripts included pediatric data for siblings. A positive family history was reported in 12 children and young people from 9 families ( Table I ; available at www.jpeds.com). 15, [27] [28] [29] [30] [31] [32] 34, 35, [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] A negative family history suggested a de novo variant, but confirmation by testing other family members was inconsistently reported. The degree of hyperpolarizing shift was obtained from the same or related reports. 2, 5, 33 Clinical Features. Clinical criteria for erythromelalgia included episodic pain and erythema in feet (n = 12), feet and hands (n = 11), or feet, hands, and ears (n = 2). Symptoms were triggered or exacerbated by heat and/or activity, and relieved by cold. In 14 cases reporting pain intensity, it was rated as severe ("severe"/"excruciating"/"10 out of 10"), often with multiple episodes each day, and constant pain was also noted in 4 inherited erythromelalgia cases. Fifteen cases (60%) reported significant skin damage or ulceration because of prolonged cold immersion (n = 11) and/or excessive rubbing or scratching (n = 4). Cooling for symptomatic relief was associated with severe hypothermia in a 6-year-old (p.L858F), 42 and hypothermia, neurologic symptoms, and pneumonia in a 15-year-old (p.L823R). 35 Mortality was associated with severe sepsis in 1 case (p.V1316A) 51 and was also reported in a sibling (p.S241T) 31, 36 (Table I) . Additional comorbidities included hypertension (p.F1449V) 52 requiring investigation and treatment (p.Q875E) 46 ; muscle hypotonia and/or joint hypermobility (p.I234T 27, 29 and p.L823R
35
); and reduced pain sensitivity (corneal anesthesia, painless fracture in 2 p.I234T cases). [28] [29] [30] Impaired growth with underdeveloped limbs or short stature was associated with normal (p.G856R), 14, 39 low (p.Q875E), 46 or unreported (p.L823R) 35 growth hormone levels. Small distal forearms, hands, distal legs, and feet were also noted in a 35-year-old with symptoms since 10 years of age (p.G856D); growth hormone levels not reported. 56 ( Table II ; available at www.jpeds.com)
Age of Onset and Genotype. Age of onset of pain and erythema ranged from 1.2 to 14 years (Figure 2 , A), with some reporting earlier onset of less specific symptoms. 27, 29, 35, 53 Sixteen different amino acid substitutions in Nav1.7 channels resulted in hyperpolarizing shifts in activation ranging from −5.3 to −18 mV ( Table I) . Greater shift tended to correlate with onset of symptoms at a younger age (r = 0.47 [95% CI 0.13-0.72], P = .016; Figure 2 , B) as previously reported.
15
Pharmacologic Management. More than 40 treatments were reported, with details of specific therapy for 15 of 25 cases. All had received agents with predominant but nonspecific sodium channel blocking activity (mexiletine, lidocaine, carbamazepine; n = 15). Efficacy data were limited, and mexiletine was variably reported to have no or minimal benefit, 15,49,50 partial benefit, 29, 35, 48 significant initial benefit, 44, 81 benefit that reduced after 6 months, 43 or sustained benefit that persisted beyond cessation of treatment. 45, 82 Additional treatments included combination therapy with antineuropathic drugs (gabapentinoids and antidepressants; n = 9); vasoactive drugs for symptomatic management and/or hypertension (n = 5); and other Age of onset and shift in voltage dependence of activation. A, The age of onset of periodic erythema and pain is shown for subjects with SCN9A mutations and inherited erythromelalgia identified by systematic review, and for cases at GOSH with inherited erythromelalgia or symptomatic erythromelalgia and negative SCN9A testing (s-EM). B, Younger age of onset of symptoms is correlated with a more negative shift in voltage dependence of activation (ie, greater hyperpolarizing shift) in DRG neurons expressing Nav1.7 channels with the related amino acid substitution.
analgesics (opioids, ketamine, or procedural interventions; n = 6) (Table III; available at www.jpeds.com).
Excluded Pediatric Cases. Several reports had limited clinical details or children were included within group data.
2,6,16,34,52,56-66 SCN9A-related inherited erythromelalgia cases in adults reporting onset of symptoms before 18 years of age are also listed (Table II) . 2, 3, 6, 17, 18, 34, 50, 59, 61, [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] Overall, pediatric onset inherited erythromelalgia was associated with 24 different Nav1.7 channel substitutions. As in the systematic review, major complications associated with excessive cooling or ice immersion were reported in additional cases: skin injury and sepsis resulting in amputations (p.L858F) 76 and mortality (p.F216S) 59, 68 ; and severe hypothermia (p.L858F 76 ) with associated cerebral symptoms (p.I848T, 73 p. F216S 68 ) ( Table II) .
GOSH Case Series
Clinical details and genetic analysis were available for 13 patients referred for management or review (SCN9A testing positive in 4; negative in 9). Episodic burning pain and erythema occurred in all patients, but skin damage related to immersion injury or repeated rubbing, and hypertension requiring management and investigation was seen only in SCN9A-positive cases (Table IV ; available at www.jpeds.com). Pain scores varied with time (eg, exacerbated by hot weather, stress, examinations) and tended to be higher and more persistent in inherited erythromelalgia cases. Patient-reported outcomes identified impaired quality of life (particularly in the physical function and school domains), emotional distress, and increased pain catastrophizing (Table V; available at www.jpeds.com). QST in 3 patients (2 inherited erythromelalgia and 1 s-EM) revealed increased sensitivity to static heat and cold in the s-EM case, but predominantly reduced sensitivity in the 2 inherited erythromelalgia cases who also had more prolonged symptoms (11 and 13 years vs 14 months). However, dynamic warm sensitivity (40°C rollers) was more intense and extended beyond the hand and into the upper arm in both inherited erythromelalgia cases. All had increased digital pressure pain sensitivity, but mechanical detection and pricking pain sensitivity was reduced in 1 inherited erythromelalgia case (p.I234T) ( Figure 3 and Table VI ; available at www.jpeds.com).
All patients had multidisciplinary assessment, physiotherapy and/or psychology interventions, and liaison with pediatricians or other medical specialists according to individual need. Mexiletine improved allodynia, activity, and sleep in 1 patient with inherited erythromelalgia (p.I848T). Pain has remained difficult to manage in 3 cases with inherited erythromelalgia, with partial benefit from higher mexiletine doses at plasma levels below those associated with toxicity (Figure 4 ; available at www.jpeds.com). Efficacy has not been tested by ceasing mexiletine. Local anesthetic sympathetic and peripheral nerve blocks at another center produced short-term benefit; and a trial of oral opioid was discontinued due to limited efficacy in a separate patient. Inpatient management of skin injury and/or infection has been required in 3 cases (Table IV) . One patient with inherited erythromelalgia (p.I234T) has developed a complex phenotype with reduced sensitivity to some forms of acute pain (venipuncture, fracture). 26 For patients with s-EM, symptomatic management alone has been used for infrequent pain episodes. One case with s-EM initially received mexiletine; changing to an anticonvulsant (once confirmed SCN9A-negative) produced similar benefit. Amitriptyline had no benefit in 1 case, but improved pain and/or sleep in 2 cases. Compared with 13 GOSH cases clinically diagnosed with erythromelalgia prior to availability of genetic testing, pharmacologic management has shifted from vasoactive to antineuropathic agents (Table III) .
Discussion
Erythromelalgia is a rare but severe pain condition in children that can be difficult to diagnose and manage. Identifying effects of SCN9A gene mutations on sensory neuron function can improve understanding and identify potential treatment targets. We report inherited erythromelalgia during childhood associated with gain-of-function mutations at multiple sites on the SCN9A gene, and a greater degree of hyperpolarizing shift in Nav1.7 channel kinetics tended to correlate with onset of symptoms at younger ages. Pain was often refractory to treatment, and attempts to gain symptomatic relief with excessive cooling or prolonged cold immersion were associated with significant morbidity. Although nonspecific sodium channel blockers were commonly used for management, current evidence is limited to uncontrolled case reports with variable reporting of efficacy and follow-up. Preliminary data from our pediatric case series suggests that episodic pain and redness alone do not differentiate SCN9A-positive from SCN9A-negative cases, which is consistent with a previous small series in adults. 37 However, severe complications and comorbidities were only seen in SCN9A-positive cases. Parent-and patient-reported questionnaires provided further description of the impact of erythromelalgia, and evaluation of somatosensory function with QST may improve evaluation of phenotype-genotype relationships in larger series.
The importance of the SCN9A gene for pain sensitivity is reflected by the association between loss-of-function mutations and congenital insensitivity to pain, and gain-offunction mutations with inherited erythromelalgia or paroxysmal extreme pain disorder (PEPD). 12, 13 Multiple inherited erythromelalgia-related mutations of the SCN9A gene have now been characterized with more marked shifts in the voltage-dependence of activation (greater than 7.6 mV hyperpolarizing shift) of Nav1.7 15 associated with inherited erythromelalgia symptom onset at younger ages, as also demonstrated by the significant negative correlation shown here. Consistent with the distribution of Nav1.7 channels on nociceptive sensory fibres, small fiber but not large fiber dysfunction has been demonstrated in children with inherited erythromelalgia. 1, 46, 52 As also reported with other causes of neuropathic pain, 83, 84 QST evaluation of small fiber function in inherited erythromelalgia demonstrated mixed patterns of sensory gain and loss in adults, 18, 55, 74, [85] [86] [87] [88] and in the 2 pediatric cases with inherited erythromelalgia reported here. The 28 the reduced sensitivity to injury associated with this genotype, [28] [29] [30] and a complex pattern that includes marked depolarization and lack of excitability in some DRG neurons expressing Nav1.7-I234T channels. 28 Erythromelalgia has been associated with significant complications during childhood and later life. 1, 89 Sixty percent of children with SCN9A-positive inherited erythromelalgia identified by systematic review, and 3 of 4 cases at our center, had significant peripheral tissue injury secondary to prolonged cold immersion or rubbing/scratching. Prolonged ice immersion and/or environmental cooling have been associated with severe hypothermia requiring intensive care 42, 68, 72, 73, 77 ; skin injury with sepsis and significant morbidity 3, 31, 50, 90, 91 ; and mortality. 36, 51, 59, 90 The extent to which hypertension 52 and increased plasma or urine catecholamines 46, 92 in pediatric inherited erythromelalgia cases are secondary to uncontrolled pain and stress is difficult to determine. Altered growth has also been noted. 35, 39, 46, 56 Potential mechanisms underlying comorbidities, and the relationship to sodium channel dysfunction or other genetic conditions, require further study.
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The severe and refractory nature of erythromelalgia pain in children is also reflected in the wide range of therapeutic interventions that have been tried for symptomatic relief.
1 Pharmacologic management is shifting from vasoactive to antineuropathic agents 93 and future pharmacotherapy for inherited erythromelalgia may increasingly be guided by genomic analysis. 14, 70, 94 Although drugs that more selectively target Nav1.7 channels are under development, 71, 75 currently available mexiletine and lidocaine are class 1B antiarrhythmic agents that nonselectively block voltage-gated sodium channels and have been associated with variable efficacy. Laboratory studies have identified beneficial actions of mexiletine specifically against Nav1.7 channels with p.I848T, 50 p.L858F, 95 and p.V872G 45 substitutions, and 1 study reported reduced axonal excitability and improvement in clinical symptoms with p.I136V, p.I848T, and p.V1316A substitutions. 48 Mexiletine doses for children with erythromelalgia have ranged from 8 to 24 mg/kg/day, 44, 81, 82 but data are insufficient to evaluate efficacy based on genotype. 50, 96 Carbamazepine is effective in patients with PEPD, 97 and specific benefit for some inherited erythromelalgia cases is supported by atomic-level structural modeling and in vitro pharmacology. 14, 70, 98 Carbamazepine normalizes the voltagedependence of activation of DRG neurons expressing Nav1.7 channels with p.V400M and p.S241T substitutions, 61,94 reduces warmth-evoked firing of p.S241T substitutions, 70 and clinical use reduced the frequency and duration of episodic pain in affected family members with these genotypes. 70 Carbamazepine partially corrects the hyperpolarized activation and reduces sensory neuron firing in Nav1.7 p.I234T channels, 98 and improved symptoms in a child with this substitution, 29 but use can be limited by side-effects. Relative efficacy and side-effects of oxcarbazepine for inherited erythromelalgia, 99 and benefit of combinations with other neuropathic agents 38 cannot be determined from the current literature.
Intravenous lidocaine infusion, epidural local anesthetic infusion, or lumbar sympathetic block have been used acutely for management of lower limb immersion injury or as a bridge to oral therapy in children with erythromelalgia, but benefit is often limited in degree and/or duration. 1, 35, 44, 48 The relative risks and potential degree and duration of benefit need to be carefully considered prior to invasive procedures for children with inherited erythromelalgia.
A biopsychosocial formulation and assessment is recommended for all children with chronic pain. 100 Although initial diagnosis of erythromelalgia is based on clinical features, confirmation or exclusion of SCN9A mutations is important for genetic counseling, informing discussions with families regarding the severity and likely course of symptoms and risk of complications, and in some cases to guide management. As many sporadic or de novo mutations have been associated with inherited erythromelalgia, lack of a family history does not preclude a genetic basis. Potential differential diagnoses that have treatment implications, such as Fabry disease, autoimmune disorders, and inflammatory arthritides should be excluded, 46, 52 and similar symptoms have been associated with mercury ingestion 101 and hydrocarbon exposure. 102 A higher proportion of female patients with clinically diagnosed erythromelalgia has been noted in pediatric 1 and adult series, 4,91,103 and some inherited erythromelalgia families report worse symptoms in female patients, 37, 38, 76 but the degree or mechanisms of sex and gender differences in inherited erythromelalgia are unclear. QST may provide a useful noninvasive test for evaluating the degree and distribution of altered small fibre function in children, 104 but potential clinical roles for monitoring disease progression or treatment response require further evaluation. A series of 32 pediatric erythromelalgia cases reported significant impairments of physical activity (in 21, 66%), school attendance (in 11, 34%), and mood (anxiety, depression, or behavior problems in 9, 28%).
1 Validated parent-and patientreported outcome measures, 46, 105 as reported in our case series, can inform multidisciplinary clinical management and could facilitate standardized evaluation of psychosocial function in multicenter populations. Education for families and patients with inherited erythromelalgia is an important component of care, 46 particularly in relation to symptomatic management and avoidance of aggravating factors, risks of prolonged cold immersion, and the relative benefits and risks of different interventions.
This systematic review has several limitations as data were retrieved from case reports or series with variable reporting of clinical features and management. The potential publication bias toward more severe cases and the lack of denominator data limit the ability to estimate the overall prevalence of inherited erythromelalgia, or the relative proportions of severe complications in SCN9A-positive vs SCN9A-negative cases. The focus here has been on SCN9A-related inherited erythromelalgia and mutations of the Nav1.7 channel for which increased activity and hyperpolarizing shifts in voltagedependent activation have been confirmed in DRG neurons expressing Nav1.7 channels with the related amino-acid substitutions. Although some cases show overlap between symptoms of inherited erythromelalgia and PEPD, 27 cases specifically reporting PEPD, which is associated with different patterns of altered channel kinetics, have not been included. 97, 106 We cannot exclude mutations affecting channels other than Nav1.7, such as Nav1.8 or Nav1.9, which may influence pain sensitivity and be associated with small fiber neuropathy. [107] [108] [109] Case series for this rare condition are necessarily small, and conclusions from our single center are limited by sample size, but provide preliminary data and suggest potential additional outcome measures for future series.
Ongoing assessment and standardized reporting in larger series are required to further explore relationships between genotype and phenotype in children with SCN9A-related inherited erythromelalgia, to confirm the proportion with genetic causes, and to identify mechanisms underlying SCN9A-negative erythromelalgia. The current findings, and significant morbidity associated with inherited erythromelalgia, highlight the need for mechanism-based therapies to improve outcome. 
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224.e1 Figure 3 . Quantitative sensory testing profiles in adolescents with erythromelalgia. A, Somatosensory measures on the thenar eminence expressed as z score comparisons to healthy control data (capped at a maximum of 2 SD difference) for individual cases with inherited erythromelalgia and p.I234T or p.I848T substitutions (n = 2), or symptomatic erythromelalgia with no SCN9A mutation (n = 1). Positive values represent increased sensitivity and negative values decreased sensitivity compared to control data. B, Dynamic allodynia was assessed by moving a hand-held brush, cool (25°C) or warm (40°C) rollers distally from the upper arm, and graded on a VRS of 0-10. All subjects reported marked allodynia to warm, with one also reporting allodynia to brush and cool. CDT, cool detection threshold; WDT, warm detection threshold; CPT, cold pain threshold; HPT, heat pain threshold; PPT, pressure pain threshold; MPT, mechanical pain threshold; WUR, wind-up ratio; MDT, mechanical detection threshold; VRS, verbal report scale. (4) CBZ (3) 3 (75%) anticonvulsant (3) antidepressant (1) 3 (75%) symptoms ( (1) CBZ (3) lidocaine (1) 11 (85%) anticonvulsant (3) antidepressant (8) 9 (69%) symptoms (9) 6 (46%) opioid (5) epidural (1) ketamine (2) 20, 21 included (1) cool (CDT) and warm detection (WDT), cold (CPT) and heat pain (HPT) thresholds using a handheld 18x18mm contact thermode (baseline 32°C, 1°C/s, limits 10°C and 50°C)(Senselab MSA Thermal Stimulator; Somedic, Sosdala, Sweden); (2) MDT with von Frey hairs (geometric mean of 10 appearance and disappearance thresholds); iii) mechanical pricking pain threshold (MPT) with ascending PinPrick Stimulators (8-512 mN) until discomfort/pain experienced (single measure is threshold) and rated 0-10 (VRS1) followed by a 1/sec train of 10 repeated stimuli (VRS10) to calculate wind-up ratio (WUR=VRS10-VRS1); (4) PPT (mean ± SD 3 measures) on middle phalanx of middle finger using hand-held 1 cm 2 algometer and optical feed-back (ramp 40 kPa/sec, maximum 1000 kPa)(SENSEBox; Somedic, Sosdala, Sweden). Dynamic allodynia was mapped using (1) mechanical brush stimulus (SENSELab Brush-05; Somedic, Sosdala, Sweden); and (2) thermal hand-held rollers at predetermined temperatures of 25°C (cool) and 40°C (warm)(Somedic RollTemp; Somedic, Sosdala, Sweden). Stimuli were moved distally from the upper arm toward the hand until any allodynia/discomfort was reported (VRS 0-10).
